MFM
NBIX icon

MD Financial Management’s Neurocrine Biosciences NBIX Stock Holding History

MD Financial Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-13,292
Closed -$1.29M – 347
2021
Q1 		$1.29M Buy
+13,292
New +$1.39M 0.04% 149

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
DCP
DSM Capital Partners Palm Beach Gardens, Florida $5.66B AUM 27.45% 1-Year Est. Return

MD Financial Management's NBIX Position: Q2 2021 in Review

MD Financial Management sold out of Neurocrine Biosciences (NBIX) in Q2 2021, closing a stake of 13,292 shares — an estimated $1.29M sold.

MD Financial Management first reported a position in NBIX in Q1 2021 and held it in 1 quarter. The position peaked at $1.29M in Q1 2021. 408 funds tracked by Wall St. Rank hold NBIX as of Q2 2021.

  • MD Financial Management reported no remaining Neurocrine Biosciences position as of Q2 2021 after selling out during the quarter.
  • MD Financial Management sold 13,292 Neurocrine Biosciences shares in Q2 2021, an estimated $1.29M.
  • MD Financial Management first reported a position in Neurocrine Biosciences in Q1 2021 and held it in 1 quarter.
  • MD Financial Management's Neurocrine Biosciences position peaked at $1.29M in Q1 2021.
  • 408 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2021.

Based on MD Financial Management's 13F filing for Q2 2021, filed 21 Jul 2021.